GUARD THERAPEUTICS INTERNATIONAL - Key Persons
Job Titles:
- Member of the Board
- Member of the Board / Board Member since December 2022. Born 1976. Fredrik Holds a PhD in Medicinal Chemistry from Göteborg University and an Executive MBA from Stockholm School of Economics
Board member since December 2022. Born 1976. Fredrik holds a PhD in Medicinal Chemistry from Göteborg University and an executive MBA from Stockholm School of Economics.
Previous experience: Fredrik has twenty years of life science experience, both entrepreneurial as founder of a handful companies as well as operational as head of research, CEO and within CMC for various pharmaceutical and biotech companies such as Pharmacia, Biovitrum, OT Chemistry, Recipharm and Oncopeptides.
Previous experience: Fredrik has twenty years of life science experience, both entrepreneurial as founder of a handful companies as well as operational as head of research, CEO and within CMC for various pharmaceutical and biotech companies such as Pharmacia, Biovitrum, OT Chemistry, Recipharm and Oncopeptides.
Other assignments: Fredrik Lehmann is a Venture Partner at Industrifonden. Chairman of the Board of Synartro AB. Board member of AnaCardio AB, AnaCardio R&D AB, AnaCardio Holding AB, Sprint Bioscience AB, Teitur Trophics ApS and board member and CEO of OT Pharmaceuticals AB.
Job Titles:
- Member of the Board
- Member of the Board / Board Member since May 2019. Born 1963. Göran Forsberg Is a PhD in Biochemistry and Associate Professor
Board member since May 2019. Born 1963. Göran Forsberg is a PhD in Biochemistry and Associate Professor.
Previous experience: Göran Forsberg has more than 30 years of experience from pharmaceutical development in both the Biotech industry and in large pharmaceutical companies. He has extensive experience of many different parts of drug development, as well as business development and investor relations. Göran Forsberg is the CEO of Cantargia AB since 2014. Prior to that, he worked as a business development manager at Active Biotech. Previous experience comes from positions at Pharmacia, KabiGen and the University of Adelaide in Australia and as Board member of Isogenica Ltd.
Job Titles:
- Chairman of the Board
- Chairman of the Board / Chairman of the Board since May 2021. Johan Bygge Holds a Master of Science from Stockholm School of Economics
Chairman of the board since May 2021. Johan Bygge holds a Master of Science from Stockholm School of Economics.
Previous experience: Chairman of EQT Asia Pacific, COO EQT, CFO Investor AB, Deputy CEO Electrolux, CFO Electrolux. Board member of Anticimex, PSM Ltd, I-Med, ILA Vietnam, Sanitec Oy, Hi3G Scandinavia, Rådet för god sed på Aktiemarknaden, etc.
Job Titles:
- Member of the Board
- Member of the Board / Board Member since May 2019. Born 1970. Johannes Hulthe Is a PhD and MSc in Economics
Previous experience: Johannes Hulthe has more than 17 years of experience from the pharmaceutical industry. Lecturer in cardiovascular prevention at Sahlgrenska University Hospital, Gothenburg. Johannes Hulthe was under 13 years employed at AstraZeneca and, when he finished in 2014, held the role of chief (vice president) in clinical drug development for heart vessels, metabolism and kidney disease.
CFO since September 2020. Born 1973. Karin Botha holds a Degree of Master of Science in Business Administration and Economics and has more than 20 years of working experience from leading roles within finance in global pharmaceutical companies such as Smithkline Beecham, GSK, Novartis and Sandoz. Previous experience includes positions such as Nordic Head of Financial Reporting and Accounting, Nordic Head of Business Planning and Analysis and Interim CFO.
Job Titles:
- Member of the Board
- Member of the Board / Board Member since October 2019. Born 1956. Lars Höckenström Holds an MBA from Stockholm University
Previous experience: Lars Höckenström has more than 35 years of finanical experience as an advisor in private and public transactions such as IPOs, rights issues and private placements within a broad range of sectors. Lars was a co-founder and Partner at Aragon Fondkommission AB, financial analyst at Öhman Fondkommission AB, Head of Research at Matthew Fondkommission AB, investment manager at Core Ventures, analyst and fund manager at Catella Kapitalförvaltning AB and analyst and corporate finance at Paretos Securities. He was also co-founder and Senior Advisor at Naventus Corporate Finance AB.
Job Titles:
- CMO / Chief Medical Officer since January 2022. Born in 1960. Dr Reusch Is a Pharmacist and Physician and Holds an MD from Essen University in Germany.
Chief Medical Officer since January 2022. Born in 1960. Dr Reusch is a pharmacist and physician and holds an MD from Essen University in Germany.
He has more than 30 years' global clinical drug development experience, most recently as Senior Medical Director at Astellas Pharma Global Clinical Development.
Job Titles:
- Head of Preclinical Science
Head of Preclinical Science since August 2020. Born in 1970. An expert in nonclinical drug discovery and developmental pharmacology, molecular biology and toxicology, Peter is responsible for all nonclinical science in Guard. He has a PhD in toxicology and more than 25 years' experience in pharmaceutical discovery and clinical development, and drug repurposing in a variety of therapeutic areas.
His previous pharmaceutical career came from AstraZeneca and Astellas Pharma as pharmacologist in projects from discovery to regulatory filing.
Job Titles:
- Head of Clinical Operations / Head of Clinical Operations since May 2021. Born 1976. Responsible for the Execution of the Company 's Clinical Studies from a Strategic and Operational Perspective.
Head of Clinical Operations since May 2021. Born 1976. Responsible for the execution of the company's clinical studies from a strategic and operational perspective.
Sara Thuresson has a Master of Science degree in biomedicine from the Karolinska Institute, has received postgraduate training in clinical drug development from Uppsala University and has been awarded the Swedish Diploma in Clinical Trials. She has more than 15 years of experience in leading multinational teams in planning, implementation and reporting of clinical studies through all development phases..
Previously, Sara Thuresson has held a number of different positions in clinical drug development at, among others, Oncopeptides, Glionova, Wilson Therapeutics, IQVIA and Medivir.
Job Titles:
- CEO
- Adjunct Associate Professor at the Karolinska Institute
Chief Executive Officer since January 2019 and Chief Medical Officer since December 2018. Born in 1976. Dr Agervald holds an MD and PhD from Uppsala University and is a board-certified specialist in internal medicine and nephrology. Dr Agervald is an associate professor and internationally recognized researcher within experimental and clinical nephrology and endocrinology. He performed parts of his PhD studies at Harvard Medical School and a postdoctoral fellowship at Indiana University School of Medicine. Dr Agervald has extensive global drug development experience in both early and later clinical stages, most recently from his position as Senior Medical Director at Astellas Pharma Global Clinical Development.
Job Titles:
- Head of Chemistry, Manufacturing and Control
Head CMC since May 2022. Born 1960 and responsible for the CMC activities within the company. Torbjörn has a bachelor's degree in chemistry, with focus on biochemistry and a supplement one year education in biotechnology. Torbjörn has more than 30 years of experience of pharmaceutical development in different roles and phases.
Previous experience includes positions as CMC responsible at Medivir AB and joint responsible for the CMC development at Aprea Therapeutics AB. The work included project management of external partners, participation in clinical study teams and preparation and performance of registration and product launch. Within Pharmacia & Upjohn Torbjörn worked within quality assurance, project management and process development.